Category

UF Startup

AavantiBio and Aldevron Announce Strategic Partnership To Develop Next-Generation Gene Therapies for Rare Genetic Diseases

UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced a long-term strategic partnership for the supply of plasmid DNA that will enable AavantiBio to advance its platform of innovative gene transfer therapies.

Axogen, Inc. Appoints John H. Johnson to Board of Directors

UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that John H. Johnson has been appointed to its Board of Directors.

RTI Surgical and Exactech Announce Strategic Partnership

UF startup and UF Innovate | Sid Martin Biotech alum RTI Surgical Holdings, Inc., a leading surgical implant company providing blue-chip OEM customers with a portfolio of tissue-based, synthetic and metal implants, has announced it has entered into a long-term strategic agreement with Gainesville-based and leading global medical device OEM Exactech, related to the development and supply of biologic bone substitutes.

SharpSpring Founder Rick Carlson Featured on Radio Cade Podcast

When Rick Carlson founded UF startup SharpSpring in 2012, he didn't think of himself as a CEO. “My co-founder and I were doing whatever it took to survive,” Carlson says, and they were responsible for everything from software development to buying office supplies. In the early days of the automated marketing software company, “there were so many failures it was hard to name them all,” according to Carlson.

AGTC Reports 12-Month Data From Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients With Mutations in the ACHM

UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, reported 12-month data from its ongoing achromatopsia (ACHM) Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.